{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:21:50Z","timestamp":1724890910284},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":170,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior Reports"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.ebr.2024.100687","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T07:40:33Z","timestamp":1718869233000},"page":"100687","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Off-label use of cannabidiol in genetic epileptic and developmental encephalopathies: A case report"],"prefix":"10.1016","volume":"27","author":[{"given":"Elisa","family":"Mannini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Misirocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Lazzari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Balella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Bottignole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maddalena","family":"Frapporti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Zinno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Florindo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liborio","family":"Parrino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlotta","family":"Mutti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ebr.2024.100687_b0005","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/epi.17237","article-title":"Methodology for classification and definition of epilepsy syndromes with list of syndromes: Report of the ILAE Task Force on Nosology and Definitions","volume":"63","author":"Wirrell","year":"2022","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.ebr.2024.100687_b0010","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1684\/epd.2021.1244","article-title":"Developmental and epileptic encephalopathies: recognition and approaches to care","volume":"23","author":"Raga","year":"2021","journal-title":"Epileptic Disord"},{"issue":"3","key":"10.1016\/j.ebr.2024.100687_b0015","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1212\/WNL.0000000000007778","article-title":"SUDEP in the North American SUDEP Registry: The full spectrum of epilepsies","volume":"93","author":"Verducci","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ebr.2024.100687_b0020","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40261-021-01003-y","article-title":"Cannabidiol in the treatment of epilepsy","volume":"41","author":"von Wrede","year":"2021","journal-title":"Clin Drug Invest"},{"issue":"6","key":"10.1016\/j.ebr.2024.100687_b0025","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/epi.15612","article-title":"Recommendations for the use of structural magnetic resonance imaging in the care of patients with epilepsy: A consensus report from the International League Against Epilepsy Neuroimaging Task Force","volume":"60","author":"Bernasconi","year":"2019","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.ebr.2024.100687_b0030","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ejmg.2013.06.012","article-title":"Clinical delineation of a patient with trisomy 12q23q24","volume":"56","author":"Bouman","year":"2013","journal-title":"Eur J Med Genet"},{"issue":"5","key":"10.1016\/j.ebr.2024.100687_b0035","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1159\/000521640","article-title":"Duplication of 12q24.21q24.33 in a girl with epilepsy, expanding the phenotype","volume":"13","author":"Plaza-Benhumea","year":"2022","journal-title":"Mol Syndromol"},{"issue":"7","key":"10.1016\/j.ebr.2024.100687_b0040","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.3390\/molecules28073271","article-title":"The polypharmacological effects of cannabidiol","volume":"28","author":"Castillo-Arellano","year":"2023","journal-title":"Molecules (Basel, Switzerland)"},{"key":"10.1016\/j.ebr.2024.100687_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2022.114237","article-title":"Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies","volume":"359","author":"Reddy","year":"2023","journal-title":"Exp Neurol"},{"key":"10.1016\/j.ebr.2024.100687_b0050","article-title":"Cannabidiol normalizes resting-state functional connectivity in treatment-resistant epilepsy","volume":"112","author":"Nenert","year":"2020","journal-title":"Epilepsy Behav E&B"},{"key":"10.1016\/j.ebr.2024.100687_b0055","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.yebeh.2019.04.008","article-title":"fMRI study of cannabidiol-induced changes in attention control in treatment-resistant epilepsy","volume":"96","author":"Allendorfer","year":"2019","journal-title":"Epilepsy Behav E&B"},{"key":"10.1016\/j.ebr.2024.100687_b0060","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.yebeh.2018.05.013","article-title":"Open-label use of highly purified CBD (Epidiolex\u00ae) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes","volume":"86","author":"Devinsky","year":"2018","journal-title":"Epilep Behav E&B"},{"key":"10.1016\/j.ebr.2024.100687_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet (London, England)"},{"issue":"3","key":"10.1016\/j.ebr.2024.100687_b0070","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jamaneurol.2020.4607","article-title":"Add-on Cannabidiol Treatment for drug-resistant seizures in tuberous sclerosis complex: A placebo-controlled randomized clinical trial","volume":"78","author":"Thiele","year":"2021","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.ebr.2024.100687_b0075","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/epi4.12699","article-title":"Real-world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study","volume":"8","author":"K\u00fchne","year":"2023","journal-title":"Epilepsia Open"},{"issue":"3","key":"10.1016\/j.ebr.2024.100687_b0080","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40263-021-00807-y","article-title":"Highly purified cannabidiol for epilepsy treatment: A systematic review of epileptic conditions beyond dravet syndrome and lennox-Gastaut Syndrome","volume":"35","author":"Lattanzi","year":"2021","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.ebr.2024.100687_b0085","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40272-021-00448-0","article-title":"Neurocognitive effects of antiseizure medications in children and adolescents with epilepsy","volume":"23","author":"Besag","year":"2021","journal-title":"Paediatr Drugs"},{"issue":"10","key":"10.1016\/j.ebr.2024.100687_b0090","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s40263-022-00955-9","article-title":"Psychobehavioural and cognitive adverse events of anti-seizure medications for the treatment of developmental and epileptic encephalopathies","volume":"36","author":"Strzelczyk","year":"2022","journal-title":"CNS Drugs"},{"issue":"8","key":"10.1016\/j.ebr.2024.100687_b0095","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1111\/epi.13815","article-title":"Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol","volume":"58","author":"Rosenberg","year":"2017","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.ebr.2024.100687_b0100","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1212\/01.wnl.0000197788.38783.09","article-title":"The impact of epilepsy surgery on quality of life in children","volume":"66","author":"Sabaz","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.ebr.2024.100687_b0105","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.yebeh.2019.03.035","article-title":"& UAB CBD Program. Quality of life in adults enrolled in an open-label study of cannabidiol (CBD) for treatment-resistant epilepsy","volume":"95","author":"Gaston","year":"2019","journal-title":"Epilep Behav E&B"},{"issue":"2","key":"10.1016\/j.ebr.2024.100687_b0110","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/WCO.0000000000001029","article-title":"New and emerging pharmacologic treatments for developmental and epileptic encephalopathies","volume":"35","author":"Vasquez","year":"2022","journal-title":"Curr Opin Neurol"}],"container-title":["Epilepsy & Behavior Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589986424000443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589986424000443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T13:56:29Z","timestamp":1724853389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589986424000443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":22,"alternative-id":["S2589986424000443"],"URL":"https:\/\/doi.org\/10.1016\/j.ebr.2024.100687","relation":{},"ISSN":["2589-9864"],"issn-type":[{"type":"print","value":"2589-9864"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Off-label use of cannabidiol in genetic epileptic and developmental encephalopathies: A case report","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebr.2024.100687","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100687"}}